Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 11/20 | 0.68 |
| ▸ | MAPT | P10636 | 11/20 | 0.68 |
| ▸ | HPGD | P15428 | 7/20 | 0.68 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.68 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.68 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.68 |
| ▸ | POLB | P06746 | 2/20 | 0.68 |
| ▸ | MEN1 | O00255 | 2/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.68 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.68 |
| ▸ | USP2 | O75604 | 1/20 | 0.68 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.68 |
| ▸ | RAB9A | P51151 | 6/20 | 0.60 |
| ▸ | NPC1 | O15118 | 4/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.60 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
| ▸ | ATM | Q13315 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13861973 | 0.91 | L3MBTL1 (0.75) | L3MBTL1MAPTHPGDCYP2C9CYP2C19 | |
| SCHEMBL15597487 | 0.82 | MAPT (0.63) | L3MBTL1MAPTHPGDCYP2C9CYP2C19 | |
| SCHEMBL13921776 | 0.81 | MAPT (0.67) | L3MBTL1MAPTHPGDCYP2C9CYP2C19 | |
| SCHEMBL13791043 | 0.81 | MAPT (0.62) | L3MBTL1MAPTHPGDCYP2C9CYP2C19 | |
| SCHEMBL89387 | 0.81 | TSHR (0.62) | L3MBTL1MAPTHPGDCYP2C9CYP2C19 | |
| SCHEMBL22714464 | 0.81 | L3MBTL1 (0.45) | L3MBTL1MAPTHPGDCYP2C9CYP2C19 | |
| SCHEMBL90673 | 0.81 | KDM4E (0.51) | L3MBTL1MAPTHPGDCYP2C9CYP2C19 | |
| SCHEMBL21358331 | 0.81 | MAPT (0.45) | L3MBTL1MAPTHPGDCYP2C9CYP2C19 | |
| SCHEMBL21331696 | 0.81 | SYK (0.48) | L3MBTL1MAPTHPGDCYP2C9CYP2C19 | |
| SCHEMBL15087903 | 0.81 | L3MBTL1 (0.45) | L3MBTL1MAPTHPGDCYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017114812-A1 | COMBINATION THERAPY OF AN HBSAG INHIBITOR AND AN INTERFERON | F. HOFFMANN-LA ROCHE AG (CH) | 2017-07-06 | — | — | WO | disclosed |
| US-8178559-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-05-15 | — | — | US | disclosed |
| US-8129411-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-03-06 | — | — | US | disclosed |
| EP-2420491-A1 | 3 , 5-substitued piperidine compounds as renin inhibitors | Novartis AG (CH) | 2012-02-22 | — | — | EP | disclosed |
| US-8084450-B2 | Organic compounds | NOVARTIS AG (CH) | 2011-12-27 | — | — | US | disclosed |
| US-20110263560-A1 | Organic Compounds | NOVARTIS AG (CH) | 2011-10-27 | — | — | US | disclosed |
| US-20090312304-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2009-12-17 | — | — | US | disclosed |
| US-20090192148-A1 | Organic Compounds | NOVARTIS AG (CH) | 2009-07-30 | — | — | US | disclosed |
| WO-2009053277-A1 | ASPARTYL PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2009-04-30 | — | — | WO | disclosed |
| WO-2009053277-A1 | ASPARTYL PROTEASE INHIBITORS | MEDIVIR AB (SE) | 2009-04-30 | — | — | WO | disclosed |
| WO-2008107365-A1 | NEW COMPOUNDS | MEDIVIR AB (SE) | 2008-09-12 | — | — | WO | disclosed |
| WO-2008107365-A1 | NEW COMPOUNDS | MEDIVIR AB (SE) | 2008-09-12 | — | — | WO | disclosed |
| WO-2007077005-A1 | 3 , 5-SUBSTITΓUED PIPERIDINE COMPOUNDS AS RENIN INHIBITORS | NOVARTIS AG (CH) | 2007-07-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090192148-A1 | Organic Compounds | REN, ACE, AGTR1 | L3MBTL1 3031/4885MAPT 1089/4885HPGD 723/4885 |
| US-20110263560-A1 | Organic Compounds | REN, ACE, OTC | L3MBTL1 4255/4885MAPT 1212/4885HPGD 343/4885 |
| US-20090312304-A1 | ORGANIC COMPOUNDS | REN, ACE, PIGO | L3MBTL1 4645/4885MAPT 1109/4885HPGD 225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.